STAT Plus: Experts push for a ‘seal of approval’ to improve the quality of medicines
Should there be a Good Housekeeping ‘seal of approval’ for prescription medicines? In a new…
Category: STAT Plus
STAT Plus: A pharma effort to work with European officials to develop new drugs is a “failure”
In a scathing report, a pair of non-governmental organizations accused the European pharmaceutical industry of…
STAT Plus: Pharmalittle: Merck enters Covid-19 vaccine race; pharma alarmed by push for U.S.-only supply chain
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: ‘One thing cancer patients don’t generally have is time’: New cancer research leader brings urgency to Sanofi
Peter Adamson joined Sanofi in late March, as the coronavirus pandemic surged around the world…
STAT Plus: Pharma panics as Washington pushes to bring drug manufacturing back to the U.S.
WASHINGTON — As the coronavirus pandemic disrupts global supply chains, lawmakers are increasingly calling on…
STAT Plus: Argenx antibody drug improves symptoms in patients with myasthenia gravis
Argenx, a Belgian drug maker, said Tuesday that its experimental medicine improved the symptoms of…
STAT Plus: Phlow CEO speaks out on criticism of his record, plans for a drug ingredient stockpile, and a huge government contract
Earlier this week, the U.S. government awarded a $354 million contract to a new public…
STAT Plus: Pharmalittle: Coronavirus vaccine may not be a cure-all; hydroxychloroquine fails in a Covid-19 study
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: AI startup transcribes and annotates doctor visits for patients
Most attempts to use artificial intelligence to transcribe doctor visits are aimed at limiting documentation…
STAT Plus: In a tale of two Mercks, the German company wins a court battle over its U.S. rival
In a setback for Merck (MRK), a court in London ruled that the big drug…
STAT Plus: After years of manufacturing problems, Akorn files for bankruptcy protection
After mounting financial and manufacturing woes, Akorn (AKRX) has filed for bankruptcy protection, a humbling…
STAT Plus: Pharmalittle: Trump’s Covid-19 vaccine chief has worrisome conflicts; U.S. provides $1.2 billion for AstraZeneca vaccine
Top of the morning to you, and a fine one it is. Once again, clear…
STAT Plus: Startup Spotlight: Aiming to speed precision cancer therapies to children
For some children with a certain type of brain tumor, treatment can mean surgery followed…
STAT Plus: Kadmon to seek FDA approval of drug targeting graft-versus-host disease following positive study outcome
Kadmon Holdings, the New York-based biotech, said Thursday that its experimental pill for chronic graft-versus-host…
STAT Plus: A secret coup and a ‘poison pill’ have frozen shares of a biotech in the race for a Covid-19 vaccine
Moderna’s work on a vaccine for coronavirus has made its founders into paper billionaires. Gilead…
STAT Plus: Biosimilars got the cold shoulder from health plans when it came to preferred coverage
As debate rages over adoption of biosimilars in the U.S., a new analysis finds that…
STAT Plus: Two years of halting progress and high turnover preceded Atul Gawande’s exit as Haven CEO
Atul Gawande’s announcement last week that he was stepping down as CEO of a high-profile…
STAT Plus: Amid conflict-of-interest criticisms, top FDA officials recuse themselves from Covid-19 vaccine approvals
A version of this article first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the…
STAT Plus: Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock
Some additional thoughts and comments on Moderna, its coronavirus vaccine, the stock’s valuation and Monday…
.jpg)
STAT Plus: Despite skepticism, Gilead’s remdesivir could become a ‘multi-year commercial opportunity’
As speculation mounts over pricing for remdesivir, a Gilead Sciences (GILD) executive suggested the experimental…
STAT Plus: Alexion becomes latest company to face pressure to sell from activist investor
When Elliott Management knocks, it’s difficult not to answer the door. The New York investment firm led…
STAT Plus: Google develops AI to identify patients at high risk of blindness
Artificial intelligence has shown an increasing ability to detect and diagnose eye diseases by analyzing…
STAT Plus: Pharmalittle: U.K. will get first access to an AstraZeneca Covid-19 vaccine; VA will continue using old malaria drug
Good morning, everyone, and welcome to another working week. We hope the weekend interlude was…
STAT Plus: Pharmalittle: France piles pressure on Sanofi over Covid-19 vaccine; GOP fails to land a punch on Bright
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Pfizer says efficacy of its Duchenne gene therapy outweighs side effects
Pfizer’s experimental gene therapy to treat Duchenne muscular dystrophy appeared to improve muscle function in…
STAT Plus: Many pivotal drug studies don’t include data on race or ethnicity, analysis finds
Amid concerns that clinical trials do not adequately represent patient populations, a new analysis finds…
STAT Plus: Pharmalittle: Sanofi walks back Covid-19 vaccine remarks; Trump to name vaccine czar with conflicts
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
CVS long-term care pharmacy pays $15 million penalty for failing to track opioids
Omnicare, which is the largest long-term care pharmacy in the U.S., agreed to pay a…
STAT Plus: Amgen’s KRAS-blocking drug shows small improvement in colon cancer response
Amgen’s experimental KRAS-blocking drug is showing a modest improvement in response rates for patients with…
STAT Plus: Some blood cancer patients see remission with Allogene’s off-the-shelf CAR-T cells, early data show
Allogene on Wednesday released the first data on tumor responses to its off-the-shelf CAR-T cell…
STAT Plus: ‘Good’ bacteria could help fight a common vaginal infection, new data show
Most companies in the microbiome space have focused on recurrent, deadly C. difficile bacterial infections….
STAT Plus: Pharmalittle: FDA rejects drug from Bristol and Bluebird; Gilead signs deals to widen access to remdesivir
Rise and shine, everyone, another busy day is on the way. Although the days may…
STAT Plus: FDA refuses application for cell therapy from Bristol and Bluebird, dealing both a major setback
The Food and Drug Administration refused to even consider an application to approve a new…
STAT Plus: Deluge of genome editing therapies end research drought for sickle cell disease
The newest publicly traded genome editing company, Beam Therapeutics, has gotten one of its experimental…
STAT Plus: Trump administration proposes a dramatic payment boost for CAR-T treatments under Medicare
WASHINGTON — The Centers for Medicare and Medicaid Services proposed a major payment bump for…
STAT Plus: Pharmalittle: Birx acknowledges remdesivir distribution was flawed; Moderna gets FDA fast track for Covid-19 vaccine
Top of the morning to you, and a fine one it is. Despite the doom…
STAT Plus: With hopes running high for Moderna’s coronavirus vaccine, the stock’s value requires an almost mythical leap of faith
Moderna is moving at unprecedented speed to develop a vaccine to prevent infection from the…
STAT Plus: Prominent Broad Institute scientist leaves to lead R&D at Genentech
A star scientist in the world of single-cell genomics and computational biology is leaving academia…
STAT Plus: Pharmalittle: Hackers linked to Iran sought Gilead Covid-19 data; NIH to test remdesivir with a Lilly drug
Hello, everyone, and welcome to another working week. We hope the weekend respite was sufficiently…
STAT Plus: Hospitals are reluctant to share data. A new effort to map brain tumors with AI is getting their help another way
It’s a contradiction that’s long slowed the forward march of artificial intelligence in medicine: Machine…
STAT Plus: Results indicate MyoKardia drug is a ‘potential game changer’ for heart condition
An experimental drug to treat an inherited, progressive heart disease clearly improved the symptoms of…
STAT Plus: Atul Gawande to depart as CEO of splashy health venture. Is it ‘a death knell’?
It seemed an ideal partnership: Three of America’s most powerful companies were teaming up with…
STAT Plus: A new Trump administration rule could increase out-of-pocket drug costs
Even as prescription drug costs remain an important pocketbook issue for many Americans, the Trump…
STAT Plus: Pharmalittle: Hydroxycholoroquine fails to help patients in a study; what will states do with the old malaria drug now?
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Maryland governor vetoes funding for a prescription drug affordability board
In a surprise move, Maryland Gov. Larry Hogan vetoed state funding for a “Prescription Drug…
STAT Plus: Apotex to pay $24 million to settle price fixing charges stemming from long-running probe
In the latest fallout from a federal probe into generic drug price fixing, Apotex agreed…
STAT Plus: Dyne Therapeutics and three other startups got venture funding a year ago. Will it be enough to get them through Covid-19?
How a venture-backed startup gets its money is suddenly more fraught than it used to…
STAT Plus: CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed
CytoDyn CEO Nader Pourhassan is already under fire for the timing of lucrative sales of…
STAT Plus: AI-centric health companies landed crucial funding in early 2020
Artificial intelligence-focused health care companies raised nearly $1 billion in funding in the first quarter…
STAT Plus: Telehealth rules have shifted rapidly during the pandemic. Are the changes here to stay?
The Trump administration appears to be leaning in favor of permanently expanding telemedicine coverage as…